Iterum Therapeutics PLC (ITRM) — Cash Flow-to-Debt Ratio
Iterum Therapeutics PLC (ITRM) has a Cash Flow-to-Debt Ratio of -0.20x as of September 2025, meaning its operating cash flow of $-7.85 Million could theoretically repay 0% of its total liabilities ($39.88 Million) in one year. See Iterum Therapeutics PLC short-term liquidity ratio to evaluate short-term liquidity relative to the company's equity base.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Iterum Therapeutics PLC Cash Flow-to-Debt Ratio (2016–2024)
Historical debt coverage capacity for Iterum Therapeutics PLC across 9 annual periods. Also explore Iterum Therapeutics PLC net asset momentum to track the company's year-over-year net asset growth rate.
Annual Cash Flow-to-Debt Ratio for Iterum Therapeutics PLC (2016–2024)
Year-by-year debt coverage analysis for Iterum Therapeutics PLC. For market capitalisation and broader financial context, see market cap of Iterum Therapeutics PLC.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.55x | $-26.77 Million | $48.68 Million | ▲ +54.3% |
| 2023 | -1.20x | $-39.33 Million | $32.66 Million | ▼ -153.1% |
| 2022 | -0.48x | $-18.47 Million | $38.83 Million | ▼ -23.9% |
| 2021 | -0.38x | $-15.84 Million | $41.27 Million | ▲ +41.3% |
| 2020 | -0.65x | $-54.53 Million | $83.35 Million | ▲ +58.5% |
| 2019 | -1.58x | $-81.92 Million | $51.99 Million | ▲ +45.5% |
| 2018 | -2.89x | $-75.89 Million | $26.25 Million | ▲ +31.4% |
| 2017 | -4.21x | $-30.60 Million | $7.26 Million | ▼ -58.5% |
| 2016 | -2.66x | $-11.30 Million | $4.25 Million | — |